China SXT Pharmaceuticals, Inc. (NasdaqCM: SXTC)
Health Care · Pharmaceuticals · CN
$3.58
-12.68% today · -100.0% 1Y
China SXT Pharmaceuticals, Inc. (NasdaqCM: SXTC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.96M and employs 56 people.
Over the last twelve months the share price has lost 100.0%, trading between 3.10 and 83.76K.
Tweenvest scores China SXT Pharmaceuticals, Inc. across four factors: quality 42/100, value 47/100, growth 0/100. Its strongest factor is value.
SXTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.96M
- Revenue (TTM)
- $1.14M
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 1.89
- 52-week high
- $83,758.33
- 52-week low
- $3.10
- Avg volume (3M)
- —
- Shares outstanding
- 477.73K
- Employees
- 56
- Next earnings
- —
About China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
- ISIN
- VGG2161P1734
- Founded
- 2005
- Listed since
- Jan 4, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.